Table 1.
Final selected T-cell epitopes used to design the Multiepitope-based subunit vaccine (MEV) construct
| Sr. No | Epitope | Protein | Position | Antigenicity | Alleles | Transmembrane helices | Docking score |
|---|---|---|---|---|---|---|---|
| MHC 1 | |||||||
| 1 | FATPMEAELARR | NY | 36–47 | 0.55 | HLA-A*68:01 | 0 | − 667.7 |
| 2 | PFATPMEAELAR | NY | 35–46 | 0.70 | HLA-A*68:01 | 0 | − 600.0 |
| 3 | HRQLQLSISSCL | NY | 22–33 | 0.58 | HLA-A*68:01 | 0 | − 682.3 |
| 4 | TTMMSDDIDWLR | AK | 7–18 | 0.98 | HLA-A*68:01 | 0 | − 699.9 |
| 5 | ECSIDDLSFYVN | AK | 211–222 | 1.1 | HLA-B*35:01 | 0 | − 718.2 |
| 6 | NATDIMEAMLKR | AK | 418–429 | 0.54 | HLA-A*68:01 | 0 | − 552.3 |
| 7 | WFESFCQFTHYR | AC | 99–110 | 1.3 | HLA-A*68:01 | 0 | − 939.4 |
| 8 | SWFESFCQFTHY | AC | 98–109 | 1.3 | HLA-A*01:01 | 0 | − 853.4 |
| 9 | LSPTEYERFFAL | AC | 38–49 | 0.69 | HLA-B*07:02 | 0 | − 686.0 |
| 10 | TRLSPRRRHHTL | PI | 436–447 | 0.61 | HLA-B*07:02 | 0 | − 756.8 |
| 11 | RLSPRRRHHTLK | PI | 437–448 | 0.83 | HLA-B*07:02 | 0 | − 600.7 |
| 12 | GRMRVVGWGLGS | LA | 146–157 | 0.55 | HLA-B*27:05 | 0 | − 747.2 |
| 13 | APRGPHGGAASA | LA | 60–71 | 0.87 | HLA-B*07:02 | 0 | − 635.3 |
| 14 | GAPRGPHGGAAS | LA | 59–70 | 1.1 | HLA-B*07:02 | 0 | − 657.9 |
| MHC 2 | |||||||
| 1 | ADHRQLQLSISSCLQ | NY | 20–34 | 0.56 | HLA-DRB1*01:01 | 0 | − 911.8 |
| 2 | YALGFQHALSPSTST | AK | 121–135 | 0.52 | HLA-DRB1*01:01 | 0 | − 800.1 |
| 3 | YERFFALLTPTWKAE | AC | 43–57 | O.51 | HLA-DRB1*04:01 | 0 | − 748.3 |
| 4 | AMPLHSWLILYSRSS | PI | 504–518 | 0.55 | HLA-DRB1*01:01 | 0 | − 905.0 |
| 5 | MPLHSWLILYSRSSH | PI | 508–522 | 0.63 | HLA-DRB1*04:01 | 0 | − 819.0 |